Press Releases

Date	Title
December 23, 2016	Oncobiologics Issues $8.35 Million of Senior Secured Notes and Warrants to Acquire 1.9 Million Shares as part of Aggregate $10.0 Million Note and 2.3 Million Warrant Offering CRANBURY, N.J. , Dec. 23, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that it entered into a
November 14, 2016	Oncobiologics Announces Presentation of Final Data from Phase 1 Clinical Study of ONS-3010 (HUMIRA® Biosimilar) CRANBURY, N.J. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today presented final data from the Phase
August 31, 2016	Oncobiologics to Present at BioCentury’s NewsMakers in the Biotech Industry Conference CRANBURY, N.J. , Aug. 31, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that its Chairman, CEO and
July 6, 2016	Oncobiologics, Inc. to Present at the 2016 Cantor Fitzgerald 2nd Annual Healthcare Conference CRANBURY, N.J. , July 06, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that its Chairman, CEO and
June 16, 2016	Oncobiologics Announces First CTA Approvals for Global Phase 3 Clinical Program for ONS-3010 (Humira® biosimilar) Clinical Program Designed to Enable Interchangeability with Humira in U.S. CRANBURY, N.J. , June 16, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal
June 10, 2016	Oncobiologics Announces Separation of Units; Trading of Common Stock and Warrants CRANBURY, N.J. , June 10, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONSIU), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody biosimilar therapeutics, today announced that the 5,833,334 units
May 18, 2016	Oncobiologics Announces Closing of Initial Public Offering of Units Cranbury, NJ – May 18, 2016 — Oncobiologics, Inc. (NASDAQ: ONSIU), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, today announced that it successfully closed its previously announced initial public
May 12, 2016	Oncobiologics Announces Pricing of Its Initial Public Offering of Units CRANBURY, N.J. , May 12, 2016 /PRNewswire/ -- Oncobiologics, Inc. (NASDAQ: ONSIU), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, today announced the pricing of its initial public offering of
December 14, 2015	Oncobiologics Expands Its Board Of Directors With The Appointment Of Three New Independent Members Oncobiologics Expands its Board of Directors with the Appointment of Three New Independent Members Cranbury, NJ – December 14, 2015 — Oncobiologics, Inc. (Oncobiologics) announces the expansion of its Board of Directors with the appointment of Albert D. Dyrness, Kurt J.
October 5, 2015	ONS-1045 (Avastin®/bevacizumab biosimilar) Meets Primary and Secondary Endpoints in Phase 1 Clinical Trial Oncobiologics Announces ONS-1045 (Avastin®/bevacizumab biosimilar) Meets Primary and Secondary Endpoints in Phase 1 Clinical Trial Cranbury, NJ – Oct. 5, 2015 — Oncobiologics, Inc. (“Oncobiologics”) announced that its bevacizumab (Avastin®) biosimilar candidate, ONS-1045, met the primary and